5:29 PM
 | 
Oct 24, 2012
 |  BC Extra  |  Financial News

Xoma raises $40 million in follow-on

Xoma Corp. (NASDAQ:XOMA) raised $40 million in a follow-on underwritten by Credit Suisse and Cowen. Xoma's gevokizumab is in Phase III testing...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >